Hydroxyurea therapy in SS children

Research output: Contribution to journalReview articlepeer-review


Children with sickle cell anemia treated with hydroxyurea at 2 years of age maintain Hb F levels above 20% for 4 to 6 years with little hematologic toxicity and no increased risks of infection. Its ability to prevent subclinical organ damage, however, is yet to be proven.

Original languageEnglish (US)
Number of pages1
Issue number7
StatePublished - Oct 2005

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Hydroxyurea therapy in SS children'. Together they form a unique fingerprint.

Cite this